Is NBIX a good stock to buy right now?

Based on our 6-factor quantitative model, NEUROCRINE BIOSCIENCES INC (NBIX) receives a "Hold" rating with a composite score of 45.7/100. It is ranked #1,350 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 59/100, Momentum 43/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for NBIX?

NEUROCRINE BIOSCIENCES INC (NBIX) has a "Hold" rating and 3-star score. The composite score of 45.7 ranks it #1,350 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is NBIX in?

NEUROCRINE BIOSCIENCES INC operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $13.30 billion. It is classified as a large-cap stock.

Does NBIX pay a dividend?

NBIX does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is NBIX's P/E ratio?

NBIX has a trailing P/E ratio of 28.89x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is NBIX?

NBIX's quality factor score is 50/100. Gross margin: 98.4%. ROE: 14.0% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is NBIX valued compared to peers?

NBIX's value factor score is 59/100 (higher = cheaper). Key multiples: P/E 28.9x, EV/EBITDA 22.2x. Valuation is roughly in line with peers.

What is NBIX's debt level?

NBIX's debt-to-equity ratio is 42%. Sector average: 32%. Low leverage suggests conservative financial management.

NBIX has a beta of 0.83, meaning it tracks the market. Stability score: 73/100.

Does NBIX have high short interest?

NBIX's short interest factor score is 16/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

NBIX Stock Analysis: Hold (Score 45.7/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
NBIX	-2.09%	-2.06%

Metric	NBIX	Benchmark
P/E Ratio	28.9x	+22%
EV/EBITDA	22.2x	+250%
Price / Book	4.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
NBIX NEUROCRINE BIOSCIENCES INC	46	50	59	43	28.9x	14.0%	98.4%	16.1%	34.7%	42.0x	$13.3B

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	1.0%	1.0%	1.0%	1.0%	1.0%	-	1.0%	1.0%	1.0%	1.0%	1.0%
Operating Margin %	0.2%	0.2%	0.2%	0.1%	0.2%	0.1%	0.2%	0.1%	0.1%	-0.8%	-9.8%
EBITDA Margin %	0.2%	0.2%	0.2%	0.1%	0.2%	0.1%	0.2%	0.1%	0.1%	-0.7%	-4.7%
Net Margin %	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.4%	0.0%	0.0%	-0.9%	-9.4%
FCF Margin %	4.5%	-	23.7%	-	-	-	20.8%	16.8%	17.0%	-62.7%	-367.6%
ROE %	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.4%	0.1%	0.0%	-0.4%	-0.4%
ROA %	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.2%	0.0%	0.0%	-0.2%	-0.4%
ROIC %	16.1%	15.0%	19.1%	8.9%	11.5%	5.9%	10.2%	6.1%	4.0%	-21.3%	-50.3%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

1.0%

Operating Margin %

0.2%

0.1%

0.2%

0.1%

0.2%

0.1%

-0.8%

-9.8%

EBITDA Margin %

0.2%

0.1%

0.2%

0.1%

0.2%

0.1%

-0.7%

-4.7%

Net Margin %

0.2%

0.1%

0.4%

0.0%

-0.9%

-9.4%

FCF Margin %

4.5%

23.7%

20.8%

16.8%

17.0%

-62.7%

-367.6%

ROE %

0.1%

0.4%

0.1%

0.0%

-0.4%

ROA %

0.1%

0.0%

0.2%

0.0%

-0.2%

-0.4%

ROIC %

16.1%

15.0%

19.1%

8.9%

11.5%

5.9%

10.2%

6.1%

4.0%

-21.3%

-50.3%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$2.7B	$2.9B	$2.4B	$1.9B	$1.5B	$1.1B	$1.0B	$788M	$451M	$162M	$30M	$20M
	—	$52M	—	$40M	$23M	—	—	—	—	—	—	—
	$2.6B	$2.8B	$2.3B	$1.8B	$1.5B	—	$1.0B	$781M	$446M	$160M	$30M	$20M
Gross Margin	98.4%	98.2%	98.6%	97.9%	98.4%	---	99.0%	99.1%	98.9%	99.2%	100.0%	100.0%
	—	$1.2B	—	$888M	$753M	$583M	—	—	—	—	—	—
Research & Development	—	—	$744M	—	—	—	$440M	$354M	$161M	$122M	$94M	$81M
Depreciation	—	—	$900K	—	—	—	$30M	$28M	$23M	$16M	$5M	$7M
Total Operating Expenses	—	$2.2B	—	$1.6B	$1.2B	$1.0B	—	—	—	—	—	—
	$592M	$619M	$571M	$251M	$249M	$103M	$163M	$72M	$37M	-$131M	-$147M	-$94M
EBIT	$592M	$619M	$571M	$251M	$249M	$103M	$163M	$72M	$37M	-$131M	-$147M	-$94M
EBITDA	$592M	$619M	$534M	$251M	$249M	$103M	$175M	$87M	$60M	-$115M	-$142M	-$84M
Operating Margin	21.2%	21.6%	24.2%	13.3%	16.7%	9.0%	15.6%	9.2%	8.2%	-81.3%	-982.5%	-476.5%
EBITDA Margin	22.1%	21.6%	22.7%	13.3%	16.7%	9.0%	16.8%	11.0%	13.2%	-71.4%	-474.7%	-424.0%
	—	—	$138M	$5M	$7M	$26M	$51M	$32M	$31M	$20M	—	$0
	—	$705M	—	$332M	$214M	$101M	—	—	—	—	—	—
Income Tax Expense	—	$227M	$145M	$82M	$59M	$12M	-$301M	$10M	$730K	—	—	—
	$455M	$479M	$341M	$250M	$155M	$90M	$407M	$37M	$21M	-$143M	-$141M	-$89M
Net Margin	16.1%	16.7%	14.5%	13.2%	10.4%	7.9%	38.9%	4.7%	4.7%	-88.2%	-940.6%	-449.8%
	$4.81	$4.81	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.23	$-1.62	$-1.63	$-1.05
Diluted EPS	$4.81	$4.67	$3.40	$2.47	$1.56	$0.92	$4.38	$0.40	$0.23	$-1.62	$-1.63	$-1.05
Weighted Avg Basic	—	100M	—	98M	96M	95M	—	—	—	—	—	—
Weighted Avg Diluted	—	103M	—	101M	99M	98M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$2.7B

$2.9B

$2.4B

$1.9B

$1.5B

$1.1B

$1.0B

$788M

$451M

$162M

$30M

$20M

—

$52M

—

$40M

$23M

—

$2.6B

$2.8B

$2.3B

$1.8B

$1.5B

—

$1.0B

$781M

$446M

$160M

$30M

$20M

Gross Margin

98.4%

98.2%

98.6%

97.9%

98.4%

---

99.0%

99.1%

98.9%

99.2%

100.0%

—

$1.2B

—

$888M

$753M

$583M

—

Research & Development

—

$744M

—

$440M

$354M

$161M

$122M

$94M

$81M

Depreciation

—

$900K

—

$30M

$28M

$23M

$16M

$5M

$7M

Total Operating Expenses

—

$2.2B

—

$1.6B

$1.2B

$1.0B

—

$592M

$619M

$571M

$251M

$249M

$103M

$163M

$72M

$37M

-$131M

-$147M

-$94M

EBIT

$592M

$619M

$571M

$251M

$249M

$103M

$163M

$72M

$37M

-$131M

-$147M

-$94M

EBITDA

$592M

$619M

$534M

$251M

$249M

$103M

$175M

$87M

$60M

-$115M

-$142M

-$84M

Operating Margin

21.2%

21.6%

24.2%

13.3%

16.7%

9.0%

15.6%

9.2%

8.2%

-81.3%

-982.5%

-476.5%

EBITDA Margin

22.1%

21.6%

22.7%

13.3%

16.7%

9.0%

16.8%

11.0%

13.2%

-71.4%

-474.7%

-424.0%

—

$138M

$5M

$7M

$26M

$51M

$32M

$31M

$20M

—

$705M

—

$332M

$214M

$101M

—

Income Tax Expense

—

$227M

$145M

$82M

$59M

$12M

-$301M

$10M

$730K

—

$455M

$479M

$341M

$250M

$155M

$90M

$407M

$37M

$21M

-$143M

-$141M

-$89M

Net Margin

16.1%

16.7%

14.5%

13.2%

10.4%

7.9%

38.9%

4.7%

-88.2%

-940.6%

-449.8%

$4.81

$3.40

$2.56

$1.61

$0.95

$4.38

$0.40

$0.23

$-1.62

$-1.63

$-1.05

Diluted EPS

$4.81

$4.67

$3.40

$2.47

$1.56

$0.92

$4.38

$0.40

$0.23

$-1.62

$-1.63

$-1.05

Weighted Avg Basic

—

100M

—

98M

96M

95M

—

Weighted Avg Diluted

—

103M

—

101M

99M

98M

—

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does NEUROCRINE BIOSCIENCES INC Do?

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. NEUROCRINE BIOSCIENCES INC (NBIX) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kevin C. Gorman and employs approximately 1,200 people, headquartered in SAN DIEGO, California. With a market capitalization of $13.3B, NBIX is one of the prominent companies in the Healthcare sector.

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Rating — Hold (April 2026)

As of April 2026, NEUROCRINE BIOSCIENCES INC receives a Hold rating with a composite score of 45.7/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NBIX ranks #1,350 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NEUROCRINE BIOSCIENCES INC ranks #107 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NBIX Stock Price and 52-Week Range

NEUROCRINE BIOSCIENCES INC (NBIX) currently trades at $128.89. The stock lost $2.75 (2.1%) in the most recent trading session. The 52-week high for NBIX is $160.18, which means the stock is currently trading -19.5% from its annual peak. The 52-week low is $84.23, putting the stock 53.0% above its annual trough. Recent trading volume was 806K shares, suggesting relatively thin trading activity.

Is NBIX Overvalued or Undervalued? — Valuation Analysis

NEUROCRINE BIOSCIENCES INC (NBIX) carries a value factor score of 59/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 28.89x, compared to the Healthcare sector average of 23.63x — a premium of 22%. The price-to-book ratio stands at 4.04x, versus the sector average of 2.75x. The price-to-sales ratio is 4.91x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NBIX trades at 22.19x EV/EBITDA, versus 6.34x for the sector.

Overall, NBIX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

NEUROCRINE BIOSCIENCES INC Profitability — ROE, Margins, and Quality Score

NEUROCRINE BIOSCIENCES INC (NBIX) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 14.0%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 9.8% versus the sector average of -33.1%.

On a margin basis, NEUROCRINE BIOSCIENCES INC reports gross margins of 98.4%, compared to 71.5% for the sector. The operating margin is 21.2% (sector: -66.1%). Net profit margin stands at 16.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 34.7% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

NBIX Debt, Balance Sheet, and Financial Health

NEUROCRINE BIOSCIENCES INC has a debt-to-equity ratio of 42.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.39x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $340M.

NBIX has a beta of 0.83, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NEUROCRINE BIOSCIENCES INC is 73/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

NEUROCRINE BIOSCIENCES INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, NEUROCRINE BIOSCIENCES INC reported revenue of $2.68B and earnings per share (EPS) of $4.81. Net income for the quarter was $455M. Gross margin was 98.4%. Operating income came in at $592M.

In FY 2025, NEUROCRINE BIOSCIENCES INC reported revenue of $2.86B and earnings per share (EPS) of $4.81. Net income for the quarter was $479M. Gross margin was 98.2%. Revenue grew 21.4% year-over-year compared to FY 2024. Operating income came in at $619M.

In Q3 2025, NEUROCRINE BIOSCIENCES INC reported revenue of $795M and earnings per share (EPS) of $2.11. Net income for the quarter was $210M. Gross margin was 98.2%. Revenue grew 27.8% year-over-year compared to Q3 2024. Operating income came in at $239M.

In Q2 2025, NEUROCRINE BIOSCIENCES INC reported revenue of $688M and earnings per share (EPS) of $1.09. Net income for the quarter was $108M. Gross margin was 98.4%. Revenue grew 16.5% year-over-year compared to Q2 2024. Operating income came in at $146M.

Over the past 8 quarters, NEUROCRINE BIOSCIENCES INC has demonstrated a growth trajectory, with revenue expanding from $590M to $2.68B. Investors analyzing NBIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NBIX Dividend Yield and Income Analysis

NEUROCRINE BIOSCIENCES INC (NBIX) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NBIX Momentum and Technical Analysis Profile

NEUROCRINE BIOSCIENCES INC (NBIX) has a momentum factor score of 43/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 16/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NBIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NEUROCRINE BIOSCIENCES INC (NBIX) ranks #107 out of 838 stocks based on the Blank Capital composite score. This places NBIX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NBIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NBIX vs S&P 500 (SPY) comparison to assess how NEUROCRINE BIOSCIENCES INC stacks up against the broader market across all factor dimensions.

NBIX Next Earnings Date

No upcoming earnings date has been announced for NEUROCRINE BIOSCIENCES INC (NBIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NBIX? — Investment Thesis Summary

NEUROCRINE BIOSCIENCES INC presents a balanced picture with arguments on both sides. Low volatility (stability score 73/100) reduces downside risk.

In summary, NEUROCRINE BIOSCIENCES INC (NBIX) earns a Hold rating with a composite score of 45.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NBIX stock.

Related Resources for NBIX Investors

Explore more research and tools: NBIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NBIX head-to-head with peers: NBIX vs AZN, NBIX vs SLGL, NBIX vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock

Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $242

Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does NEUROCRINE BIOSCIENCES INC Do?

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Rating — Hold (April 2026)

NBIX Stock Price and 52-Week Range

Is NBIX Overvalued or Undervalued? — Valuation Analysis

NEUROCRINE BIOSCIENCES INC Profitability — ROE, Margins, and Quality Score

NBIX Debt, Balance Sheet, and Financial Health

NEUROCRINE BIOSCIENCES INC Revenue and Earnings History — Quarterly Trend

NBIX Dividend Yield and Income Analysis

NBIX Momentum and Technical Analysis Profile

NBIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

NBIX Next Earnings Date

Should You Buy NBIX? — Investment Thesis Summary

Related Resources for NBIX Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock

Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why

Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $242

Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story